Cardiovascular Effects of Stimulators of Soluble Guanylate Cyclase Administration: A Meta-analysis of Randomized Controlled Trials

• Published in: Current atherosclerosis reports Vol. 26; no. 5; pp. 177 - 187
• Main Authors: Stamerra, Cosimo Andrea, Di Giosia, Paolo, Giorgini, Paolo, Jamialahmadi, Tannaz, Sahebkar, Amirhossein
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.05.2024
• Subjects: Angiology; Cardiology; Guanylyl Cyclase C Agonists - therapeutic use; Heart Failure - drug therapy; Heart Failure - mortality; Humans; Medicine; Medicine & Public Health; Natriuretic Peptide, Brain - therapeutic use; Peptide Fragments - therapeutic use; Randomized Controlled Trials as Topic; Review; Soluble Guanylyl Cyclase - metabolism; Stroke Volume - drug effects; Topical Collection on Vascular Biology; Treatment Outcome; Heart failure; NT-pro-BNP; Oxidative stress; Cardiovascular effects; Mortality; Soluble guanylate cyclase stimulators; Ejection fraction

Purpose of review Heart failure (HF) is one of the main causes of cardiovascular mortality in the western world. Despite great advances in treatment, recurrence and mortality rates remain high. Soluble guanylate cyclase is an enzyme which, by producing cGMP, is responsible for the effects of vasodil...